Can Gubra drive value creating partner programs?
Gubra Partner Programs
Having engaged in a number of large partner programs, we have profound scientific capabilities and experience leading both target and drug discovery programs within Diabetes, Obesity, NASH and Gastrointestinal diseases.
Besides offering all necessary disciplines in-house (from molecular and in vivo pharmacology to peptide chemistry), we have professional project managers leading our partner programs. Projects are managed to meet deadlines and stay within budget while never compromising our high-quality outputs.
There is a need for novel therapeutics with an added benefit to diabetes patients within diabetic complications, convenience, cardiovascular effects and risk of hypoglycemia. Reach out to discuss opportunities within diabetes.
Currently we are engaged in a partner program with Boehringer Ingelheim, however, we also have a number of other obesity partner programs ready for partnering.
Short Bowel Syndrome (SBS) is an orphan disease on the rise with significant unmet medical needs. We have a program focusing on GLP1/GLP2 co-agonist for Short Bowel Syndrome ready for partnering.